RecruitingNot Applicable

Improving Health Outcomes With Kefir

Canada156 participantsStarted 2026-03-24

Plain-language summary

The purpose of the study is to ascertain whether traditional kefir not only enhances vascular health but also contributes to improved immune outcomes in both male and female participants at higher risk or living with Type 2 Diabetes (T2D) after 12 weeks of treatment.

Who can participate

Age range24 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. females and males (24-70 years old) living in Edmonton (or Edmonton area/driving distance);
✓. overweight or obesity (BMI \>25 Caucasian, \>23 Asian);
✓. at higher risk of T2D (fasting blood glucose ≥ 5.6 - 6.9 mmol/L or/and HbA1C ≥ 5.5 - 6.4%); or
✓. with diagnosis of T2D (fasting blood glucose ≥ 7.0 mmol/L or/and HbA1C ≥ 6.5%).

Exclusion criteria

✕. a usual high intake (maximum intake 3 servings/week) of fermented foods excluding cheese (i.e., kefir, kombucha, kimchi, etc.) for the past 3 months;
✕. gastrointestinal (GI) disorders of any kind;
✕. being pregnant or breastfeeding;
✕. monogenic dyslipidemias and endocrine disorders except for diabetes;
✕. use of medications within the last 3 months (i.e., antibiotics or antifungals, corticosteroids, methotrexate, or immunosuppressive cytotoxic agents);
✕. any health conditions deemed to interfere with primary outcomes at the investigator's discretion (e.g., kidney disease, liver disease, cancer, GI surgery, heavy alcohol consumption, etc.);
✕. having a pacemaker or any electrical medical device that prevents the individual from undergoing the bioelectrical impedance analysis bioimmunoassay (BIA) test."

What they're measuring

Change in Glycated Hemoglobin (HbA1c) Levels (Percentage)

Timeframe: Baseline, 6 weeks, 12 weeks

Trial details

NCT IDNCT06695221

SponsorUniversity of Alberta

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12

Contact for this trial

Paulina Aldana Hernandez, PhD

780-492-9506 paldana@ualberta.ca

View on ClinicalTrials.gov More Systemic Inflammatory Response trials